Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB and Schwarz Pharma to promote Neupro

UCB and Schwarz Pharma to promote Neupro

18th July 2007

UCB and Schwarz Pharma have announced that the firms are to co-promote Neupro (rotigotine transdermal system), a treatment for the symptoms of the early stages of idiopathic Parkinson’s disease.

The firms will use dedicated sales teams to approach doctors treating the condition across the US, while the companies are also participating in the launch of a public education effort – PD-Aware – attempting to increase the profile of the disease and the benefits of recent advances in medical treatment.

Neupro is a non-ergolonic dopamine receptor-agonist designed to imitate the action of naturally-produced dopamine to facilitate enhanced motor functioning which is now available in a patch formulation for once-daily application.

The treatment was approved by the US Food and Drug Administration in May 2007 following a number of clinical trials involving over 1,500 patients showing the compound to be effective and well-tolerated in early-stage Parkinson’s disease patients.

C Warren Olanow, professor and chair of neurology and professor of neuroscience at the Mount Sinai School of Medicine, said: “Disabling Parkinson’s symptoms can be well controlled with available medications, but may return as the effects of Parkinson’s disease medications wear off.”

He added that Neupro is the first available transdermal formulation of a Parkinson’s disease drug that can provide 24-hour delivery of treatment through the day and night.

In January 2007, Schwarz Pharma received marketing authorisation in the European Union for Neupro as a treatment for all stages of Parkinson’s disease.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.